Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTIA: Tisagenlecleucel + Pembrolizumab in r/r DLBCL
NCT03630159Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- CAR-T Cells
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Primary endpoints: Percent of participants recieving pembrolizumab per protocol schedule, Incidence of dose limiting toxicities and 1 more. Started Oct 2018; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03630159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630159.